James Crowe Jr., MD, a physician-scientist on the front lines of global research to eliminate human susceptibility to COVID-19 and other illnesses, is Vanderbilt University’s winner of the 2021 Southeastern Conference Faculty Achievement Award.

The U.S. government has reserved up to 700,000 doses of a monoclonal antibody cocktail against the COVID-19 virus discovered at Vanderbilt University Medical Center and developed by AstraZeneca, officials have announced.

The discovery of monoclonal antibodies that neutralize Rift Valley Fever Virus — an emerging infection with pandemic potential — lays the foundation for future therapeutic antibody development.

Despite an impressive vaccination effort that exceeds 2 million shots a day, rates of COVID-19 are again on the rise in several parts of the United States, as is the spread of highly transmissible variants of the virus.

A monoclonal antibody “cocktail” developed at Vanderbilt University Medical Center to neutralize the COVID-19 virus is effective against all known strains, or variants, of the virus, according to a report published today in the journal Nature Medicine.

Evotec, a drug company headquartered in Hamburg, Germany, has begun a phase 1 clinical trial of a monoclonal antibody against the chikungunya virus that was identified at Vanderbilt University Medical Center.

Julie Carell Stadler, Kathryn Carell Brown and Edie Carell Johnson have made a commitment to endow a new chair in Pediatric Infectious Diseases research at Vanderbilt University School of Medicine. The inaugural chair holder of the Edie Carell Johnson Chair in Pediatrics will be announced this spring.